These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6944548)

  • 1. Body weight and prognosis in breast cancer.
    Boyd NF; Campbell JE; Germanson T; Thomson DB; Sutherland DJ; Meakin JW
    J Natl Cancer Inst; 1981 Oct; 67(4):785-9. PubMed ID: 6944548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in fat intake is not associated with weight loss in most women after breast cancer diagnosis: evidence from a randomized controlled trial.
    Rock CL; Thomson C; Caan BJ; Flatt SW; Newman V; Ritenbaugh C; Marshall JR; Hollenbach KA; Stefanick ML; Pierce JP
    Cancer; 2001 Jan; 91(1):25-34. PubMed ID: 11148556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
    Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
    Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian ablation as treatment for young women with breast cancer.
    Davidson NE
    J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial.
    Spiegel D; Butler LD; Giese-Davis J; Koopman C; Miller E; DiMiceli S; Classen CC; Fobair P; Carlson RW; Kraemer HC
    Cancer; 2007 Sep; 110(5):1130-8. PubMed ID: 17647221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in body weight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet.
    Thomson CA; Rock CL; Giuliano AR; Newton TR; Cui H; Reid PM; Green TL; Alberts DS;
    Eur J Nutr; 2005 Feb; 44(1):18-25. PubMed ID: 15309460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New methods in the treatment of breast cancer].
    Semiglazov VF
    Vopr Onkol; 1997; 43(1):22-6. PubMed ID: 9133082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body size and breast cancer prognosis: a statistical explanation of the discrepancies.
    Suissa S; Pollak M; Spitzer WO; Margolese R
    Cancer Res; 1989 Jun; 49(11):3113-6. PubMed ID: 2655890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence in breast cancer. Analysis with frailty model.
    Gohari MR; Mahmoudi M; Mohammed K; Pasha E; Khodabakhshi R
    Saudi Med J; 2006 Aug; 27(8):1187-93. PubMed ID: 16883450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight changes after adjuvant treatment in Korean women with early breast cancer.
    Han HS; Lee KW; Kim JH; Kim SW; Kim IA; Oh DY; Im SA; Bang SM; Lee JS
    Breast Cancer Res Treat; 2009 Mar; 114(1):147-53. PubMed ID: 18365310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.